Search results
Results from the WOW.Com Content Network
Breakthrough T1D was founded in 1970 by a group of parents of children living with type 1 diabetes. [9] The founding members formed the organization with the intent to find a cure for type 1 diabetes and its complications by supporting research.
Studies with monkeys show that injecting high-insulin-producing forms of these cells into the animals can “cure” type-1 diabetes for about six months. Human trials are underway.
In the book, Trudeau claims that there are all-natural cures for serious illnesses including cancer, herpes, arthritis, AIDS, acid reflux disease, various phobias, depression, obesity, diabetes, multiple sclerosis, lupus, chronic fatigue syndrome, attention deficit disorder, muscular dystrophy, and that these are being deliberately hidden and suppressed from the public by the Food and Drug ...
The Juvenile Diabetes Cure Alliance (JDCA) is a registered 501(c)(3) non-profit organization dedicated to developing a Practical Cure for type 1 diabetes.The organization advocates for increasing type 1 diabetes cure research and publishes reports on a variety of related topics, including research progress, fundraising utilization, and donor priorities.
In a downtown Miami tower, 27 researchers peer into microscopes, take specimens from refrigerators, and drop liquid into test tubes in their daily search for a cure for diabetes. In the tower’s ...
For premium support please call: 800-290-4726 more ways to reach us
Theranos Inc. (/ ˈ θ ɛr. ə n. oʊ s /) was an American privately held corporation [5] that was touted as a breakthrough health technology company. Founded in 2003 by then 19-year-old Elizabeth Holmes, Theranos raised more than US$700 million from venture capitalists and private investors, resulting in a $9 billion valuation at its peak in 2013 and 2014.
A breakthrough therapy designation can be assigned to a drug if "it is a drug which is intended alone or in combination with one or more other drugs to treat a serious or life threatening disease or condition" and if the preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as ...